We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ROL:NYSERollins, Inc. Analysis

Data as of 2026-05-23 - not real-time

$53.46

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Rollins, Inc. (ROL) is trading at $53.46, well below its 52‑week high of $66.14 but also under its 20‑day SMA of $54.09 and 50‑day SMA of $54.25, signaling a bearish price stance. The MACD histogram is negative and the RSI sits at 44.7, indicating momentum weakness, while volume is trending upward, suggesting sellers are in control. Fundamentally, the company delivers strong profitability with a 13.8% net margin, 38.7% ROE and healthy free cash flow of $521 M, supporting a 1.37% dividend that is covered by a 64% payout ratio. However, valuation metrics are stretched – a trailing PE of 49×, PB of 18.7× and a DCF‑derived fair value of $19.69 imply the stock is overvalued relative to intrinsic expectations. The sector’s cyclical nature and a 30‑day volatility of 17.3% add to downside risk, though the low beta of 0.27 points to limited market‑wide sensitivity. Given the bearish technical picture, high valuation gap, and modest upside from the DCF model, the short‑term outlook is cautious, while the underlying cash‑generating business and sustainable dividend support a more neutral stance for medium to long horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD and price below short‑term moving averages
  • High valuation relative to DCF fair value
  • Rising volume on down‑side moves

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong ROE and cash flow generation
  • Sustainable dividend yield
  • Elevated valuation may limit upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Durable franchise model with long‑term contracts
  • Low beta indicating limited systematic risk
  • Potential for valuation re‑rating as market normalizes

Key Metrics & Analysis

Financial Health

Revenue Growth10.20%
Profit Margin13.77%
P/E Ratio49.0
ROE38.67%
ROA14.98%
Debt/Equity77.23
P/B Ratio18.7
Op. Cash Flow$649.6M
Free Cash Flow$521.4M

Technical Analysis

TrendBearish
RSI44.7
Support$51.95
Resistance$57.36
MA 20$54.09
MA 50$54.25
MA 200$57.86
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair Value$19.69
Target Price$64.06
Upside/Downside19.83%
GradeOvervalued
TypeGrowth
Dividend Yield1.37%

Risk Assessment

Beta0.27
Volatility17.32%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.